<SEC-DOCUMENT>0001178913-21-001346.txt : 20210415
<SEC-HEADER>0001178913-21-001346.hdr.sgml : 20210415
<ACCEPTANCE-DATETIME>20210415160121
ACCESSION NUMBER:		0001178913-21-001346
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210415
FILED AS OF DATE:		20210415
DATE AS OF CHANGE:		20210415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioLineRx Ltd.
		CENTRAL INDEX KEY:			0001498403
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35223
		FILM NUMBER:		21828483

	BUSINESS ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871
		BUSINESS PHONE:		972-2-548-9100

	MAIL ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioLineRX, Ltd.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2125882.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">WASHINGTON, D.C. 20549</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25; font-size: 14pt;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">FORM 6-K</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">For the month of April 2021</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Commission file number: 001-35223</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">_______________________</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">BioLineRx Ltd.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">_______________________</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">2 HaMa&#8217;ayan Street<br>
        Modi&#8217;in 7177871, Israel</div>
      <div style="text-align: center; line-height: 1.25;">&#160;(Address of Principal Executive Offices)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">_______________________</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: &#160; &#160; &#160; &#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form 20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160; &#160; &#160; &#160; &#160; Form 40-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; line-height: 1.25;">On April 15, 2021 the registrant issued the press release which is filed as <a href="exhibit_1.htm"><u>Exhibi</u>t
        </a><a href="exhibit_1.htm">1</a> to this Report on Form 6-K.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">The first two paragraphs and the table under &#8220;summary data&#8221; of the press release attached to this Form 6-K are hereby incorporated by reference into all effective registration statements filed by the registrant under
        the Securities Act of 1933.</div>
      <div style="line-height: 1.25;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"> </div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z647d147cd9c64de69e073b52f721d479">

        <tr>
          <td style="width: 49.97%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">BioLineRx Ltd.</div>
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.97%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 23.96%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Philip A. Serlin</div>
          </td>
          <td style="width: 22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.97%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23.96%; vertical-align: top;">
            <div style="line-height: 1.25;">Philip A. Serlin</div>
          </td>
          <td style="width: 22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.97%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23.96%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Executive Officer</div>
          </td>
          <td style="width: 22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">Dated: April 15, 2021 </div>
    <div style="line-height: 1.25;"><br>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<DESCRIPTION>EXHIBIT 1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="text-align: right;">
          <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u><font style="font-weight: bold;">Exhibit 1</font></u><br>
        </div>
        <img width="285" height="38" src="image00001.jpg"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">For Immediate Release</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">BioLineRx Announces Presentation at 2021 American </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Association for Cancer Research (AACR) Annual Meeting</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">- Poster includes analysis of results by liver metastases, further strengthening </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">results reported in December 2020 of the COMBAT/KEYNOTE-202 triple </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">combination study of motixafortide in metastatic pancreatic cancer &#8211;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">- Company also on track to report final data from Phase 3 GENESIS trial of </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">motixafortide in stem cell mobilization in next few weeks -</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Tel Aviv, Israel, April 15, 2021 &#8211; BioLineRx Ltd. (NASDAQ/TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on
      oncology, today announced that the Company has presented a poster at the AACR Annual Meeting, which is being held April 10-15 on a virtual basis.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">The poster, entitled: &#8220;A Multi-Center Phase 2a Trial of the CXCR4 inhibitor Motixafortide (BL-8040) in Combination with Pembrolizumab
        and Chemotherapy, in Patients with Metastatic Pancreatic Adenocarcinoma, the COMBAT Study,&#8221; includes new analyses from the Company&#8217;s Phase 2a COMBAT/KEYNOTE-202 triple combination study of motixafortide in metastatic pancreatic cancer, further
        detailing the clinical effect of the combination in patients with and without liver metastases.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">The COMBAT/KEYNOTE-202 study evaluated BioLineRx&#8217;s lead clinical candidate, motixafortide, in combination with KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>and
      chemotherapy in patients with advanced pancreatic ductal adenocarcinoma, or PDAC. <u>Top-line results from the study</u> were announced in December 2020.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#8220;Liver metastases are a critical factor driving poor prognoses for patients with metastatic PDAC,&#8221; stated Dr. Abi Vainstein, Chief
        Medical Officer of BioLineRx. &#8220;We are very pleased to present this additional analysis, which further strengthens the results reported from the COMBAT/KEYNOTE-202 trial in December 2020, since not only were substantially all patients initially
        diagnosed with stage 4 disease, but the vast majority (~80%) of the patients had liver metastases, emphasizing the extremely difficult patient population in this study. These data should be further confirmed in a randomized trial, and we continue
        to work diligently to define next steps for the program with potential collaboration partners.&#8221;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Summary data:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="2" border="0" id="z37608cb4c973433897fd6ed707618f64" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 22.35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Endpoint</div>
          </td>
          <td style="width: 25.38%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Evaluable Patients (N=38)</div>
          </td>
          <td style="width: 25.38%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Liver Metastases</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(N=30)</div>
          </td>
          <td style="width: 26.89%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Liver Metastases</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(N=8)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">mOS (months)</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(95% CI)</div>
          </td>
          <td style="width: 25.38%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">6.5</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(4.5-9.6)</div>
          </td>
          <td style="width: 25.38%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">5.9</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(4.4-9.6)</div>
          </td>
          <td style="width: 26.89%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">8.4</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(3.5-10.8)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">mPFS (months)</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(95% CI)</div>
          </td>
          <td style="width: 25.38%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">4.0</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(1.5-5.6)</div>
          </td>
          <td style="width: 25.38%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">1.9</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(1.5-5.7)</div>
          </td>
          <td style="width: 26.89%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">5.4</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(1.5-8.0)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ORR</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(95% CI)</div>
          </td>
          <td style="width: 25.38%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">21.1%</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(8.1%-34.0%)</div>
          </td>
          <td style="width: 25.38%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">16.7%</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(3.3%-30.0%)</div>
          </td>
          <td style="width: 26.89%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">37.5%</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(4.0%-71.0%)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">DCR</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(95% CI)</div>
          </td>
          <td style="width: 25.38%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">63.2%</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(47.8%-78.5%)</div>
          </td>
          <td style="width: 25.38%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">56.7%</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(38.9%-74.4%)</div>
          </td>
          <td style="width: 26.89%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">87.5%</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(64.6%-100.0%)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;We believe these incremental data provide strong support for continued development of motixafortide as the backbone of a new regimen
        for the treatment of PDAC and will likely prove beneficial as we advance discussions with potential collaboration partners,&#8221; stated Philip Serlin, Chief Executive Officer of BioLineRx. &#8220;At the same time, we are very much looking forward to final
        data from our Phase 3 GENESIS study in stem cell mobilization in the next few weeks, which we hope will give us a clear pathway to potential registration and highlight the versatility of motixafortide across both hematological and solid tumor
        cancer types.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><u>A copy of the poster</u> is now available on
        the Company&#8217;s website, <u>www.biolinerx.com</u>.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About BioLineRx</div>
    <div style="text-align: justify; line-height: 1.25;">BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company&#8217;s business model
      is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The Company&#8217;s lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in
      stem-cell mobilization for autologous bone-marrow transplantation. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and chemotherapy under a clinical
      trial collaboration agreement with MSD (BioLineRx owns all rights to motixafortide), and is currently being studied in combination with LIBTAYO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and chemotherapy as a first-line PDAC therapy.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being
      investigated in a Phase 1/2a study</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">For additional information on BioLineRx, please visit the Company&#8217;s website at <u>www.biolinerx.com</u>, where you can review the Company&#8217;s SEC filings, press releases, announcements and events.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking
      statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These
      forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or
      implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress
      and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or
      clinical trials; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic
      candidates; BioLineRx's ability to establish and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic
      candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of
      protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of
      BioLineRx's expenses, future revenues, capital requirements and its needs for additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and
      BioLineRx's industry; risks related to the COVID-19 pandemic; and statements as to the impact of the political and security situation in Israel on BioLineRx's business. These and other factors are more fully discussed in the "Risk Factors" section of
      BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on February 23, 2021. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be
      relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Contact:</div>
      <div style="text-align: justify; line-height: 1.25;">Tim McCarthy</div>
      <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
      <div style="text-align: justify; line-height: 1.25;">+1-212-915-2564</div>
      <div style="text-align: justify; line-height: 1.25;"><u>tim@lifesciadvisors.com</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">or</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Moran Meir</div>
      <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
      <div style="text-align: justify; line-height: 1.25;">+972-54-476-4945</div>
      <div style="text-align: justify; line-height: 1.25;"><u>moran@lifesciadvisors.com</u></div>
      <div style="text-align: justify; line-height: 1.25;"><u> <br>
        </u></div>
      <div style="text-align: justify; line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u> </u></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !8 HP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *R/%&J3Z)X5U35+9(WGM+9YD60$J2
M!D9P0<?C6O7-_$'_ ))YX@_Z\9?_ $$U4=9(3V/'_P#A>WBC_GPTC_OS+_\
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M_';_ )$>S_[",?\ Z+DKY[KZ$^.W_(CV?_81C_\ 1<E?/=/!_P (,7\9[!\
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MC_%1],4445XAZH4444 %%%% !1110!XO\??]7HO^_)_(5XI7M?Q]_P!7HO\
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MY1^(?_)1=?\ ^OH_^@K7U=7RC\0_^2BZ_P#]?1_]!6G@?C?H&+_AF!9_\?\
M:_\ 7=/_ $(5]ER$K&S#J 37QI9_\?\ :_\ 7=/_ $(5]E3?ZF3_ '358[>)
M.#^%GQSJ;%M7OF/5KF4G_OLUN_#W^S/^$VL?[9^Q_8,/YGVS;Y73C.[BL#4?
M^0I>_P#7Q)_Z$:KUW./-"QQ\W+4N?3W_ !;#_J4/_):C_BV'_4H?^2U?,-%<
MWU3^\S?ZU_=1]/?\6P_ZE#_R6H_XMA_U*'_DM7S#11]4_O,/K7]U'T]_Q;#_
M *E#_P EJ4#X8D@ >$"2< ?Z-7S!3X/^/F'_ *Z+_,4/"?WF-8F[MRH^MO\
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M[:=8T\A"HP5SSDFHJ8:<(\TBX5X3=D<I\??]7HO^_)_(5XI7M?Q]_P!7HO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
